OTCMKTS:MLNTQ

Melinta Therapeutics Stock Forecast, Price & News

$0.11
0.00 (0.00 %)
(As of 04/20/2020)
Add
Compare
Today's Range
$0.11
Now: $0.11▼
$0.11
50-Day Range
$0.11
MA: $0.11▼
$0.11
52-Week Range
$0.06
Now: $0.11▼
$8.60
Volume32,900 shs
Average Volume213,569 shs
Market Capitalization$1.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MLNTQ
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.melinta.com
Phone908-617-1309
Employees290
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$96.43 million
Price / Sales0.02
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares13,751,000
Market Cap$1.51 million
Next Earnings DateN/A
OptionableOptionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

MarketRank™

Overall MarketRank™

0.17 out of 5 stars

Medical Sector

1806th out of 2,016 stocks

Pharmaceutical Preparations Industry

723rd out of 771 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$0.11
0.00 (0.00 %)
(As of 04/20/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive MLNTQ News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNTQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Melinta Therapeutics (OTCMKTS:MLNTQ) Frequently Asked Questions

What stocks does MarketBeat like better than Melinta Therapeutics?

Wall Street analysts have given Melinta Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Melinta Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the following people:
  • Ms. Jennifer A. Sanfilippo, Interim CEO & Director (Age 41)
  • Dr. Thomas A. Steitz, Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen, Co-Founder
  • Mr. Peter J. Milligan, CFO & Sec. (Age 52)

Who are some of Melinta Therapeutics' key competitors?

Some companies that are related to Melinta Therapeutics include Wellness Center USA (WCUI), Intellipharmaceutics International (IPCIF), International Stem Cell (ISCO), Helix BioMedix (HXBM), Amarantus BioScience (AMBS), BriaCell Therapeutics (BCTXF), American Bio Medica (ABMC), FutureWorld (FWDG), Akorn (AKRXQ), VG Life Sciences (VGLS), Boston Therapeutics (BTHE), RespireRx Pharmaceuticals (RSPI), Innovus Pharmaceuticals (INNVD), ImmunoCellular Therapeutics (IMUCD) and VIVUS (VVUSQ).
View all of MLNTQ's competitors.

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the OTCMKTS under the ticker symbol "MLNTQ."

How do I buy shares of Melinta Therapeutics?

Shares of MLNTQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Melinta Therapeutics' stock price today?

One share of MLNTQ stock can currently be purchased for approximately $0.11.

How much money does Melinta Therapeutics make?

Melinta Therapeutics has a market capitalization of $1.51 million and generates $96.43 million in revenue each year.

How many employees does Melinta Therapeutics have?

Melinta Therapeutics employs 290 workers across the globe.

What is Melinta Therapeutics' official website?

The official website for Melinta Therapeutics is www.melinta.com.

Where are Melinta Therapeutics' headquarters?

Melinta Therapeutics is headquartered at 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The company can be reached via phone at 908-617-1309 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.